synergy pci a subset analysis of the synergy trial n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
SYNERGY PCI A Subset analysis of the SYNERGY trial PowerPoint Presentation
Download Presentation
SYNERGY PCI A Subset analysis of the SYNERGY trial

Loading in 2 Seconds...

play fullscreen
1 / 4

SYNERGY PCI A Subset analysis of the SYNERGY trial - PowerPoint PPT Presentation


  • 114 Views
  • Uploaded on

SYNERGY PCI A Subset analysis of the SYNERGY trial. 4,687 high-risk ACS patients undergoing PCI after randomization to unfractionated heparin or enoxaparin. Enoxaparin 1mg/kg sc every 12 hours plus additional 0.3 mg/kg IV at time of PCI if procedure was more than 8 hrs after last sc dose.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'SYNERGY PCI A Subset analysis of the SYNERGY trial' - lee-hicks


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
synergy pci a subset analysis of the synergy trial
SYNERGY PCIA Subset analysis of the SYNERGY trial

4,687 high-risk ACS patients undergoing PCI after randomization to unfractionated heparin or enoxaparin

Enoxaparin

1mg/kg sc every 12 hours plus additional 0.3 mg/kg IV at time of PCI if procedure was more than 8 hrs after last sc dose

Unfractionated heparin

60 U/kg bolus, then 12 U/kg per hour adjusted to an activated partial thromboplastin time of 50 to 70 seconds

Primary Endpoint: Death/MI at 30 days

synergy pci
SYNERGY PCI

Death / MI by intent-to-treat analysis at 30 days

Death

MI

Death or MI

P=NS

P=NS

%

P=NS

synergy pci1
SYNERGY PCI

Bleeding in the intent-to-treat analysis at 30 days

TIMI minor

TIMI major

GUSTO severe

%

P<0.05

synergy pci2
SYNERGY PCI
  • Among high-risk ACS patients undergoing PCI, the rate of death/MI at 30 days was not significantly different between patients treated with enoxaparin or unfractionated heparin.
  • Primary endpoint data for PCI patients is consistent with primary SYNERGY trial
  • As in primary SYNERGY trial, enoxaparin was associated with an increase in TIMI major bleeding